Endometrial intraepithelial neoplasia: Difference between revisions
Jump to navigation
Jump to search
| Line 115: | Line 115: | ||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
*Progestin therapy is recommended among patients with endometrial intraepithelial neoplasia and follow-up biopsy every 6 months until 3 negative biopsies .<ref name="pmid230905353">{{cite journal |vauthors=Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL |title=Management of endometrial precancers |journal=Obstet Gynecol |volume=120 |issue=5 |pages=1160–75 |date=November 2012 |pmid=23090535 |pmc=3800154 |doi=http://10.1097/AOG.0b013e31826bb121 |url=}}</ref> | *Progestin therapy is recommended among patients with endometrial intraepithelial neoplasia and follow-up biopsy every 6 months until 3 negative biopsies .<ref name="pmid230905353">{{cite journal |vauthors=Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL |title=Management of endometrial precancers |journal=Obstet Gynecol |volume=120 |issue=5 |pages=1160–75 |date=November 2012 |pmid=23090535 |pmc=3800154 |doi=http://10.1097/AOG.0b013e31826bb121 |url=}}</ref><ref name="OwingsQuick20143">{{cite journal|last1=Owings|first1=Richard A.|last2=Quick|first2=Charles M.|title=Endometrial Intraepithelial Neoplasia|journal=Archives of Pathology & Laboratory Medicine|volume=138|issue=4|year=2014|pages=484–491|issn=0003-9985|doi=10.5858/arpa.2012-0709-RA}}</ref> | ||
=== Surgery === | === Surgery === | ||
*Hysterectomy is the mainstay of treatment for [endometrial intraepithelial neoplasia to prevent endometrial carcinoma.<ref name="pmid23090535">{{cite journal |vauthors=Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL |title=Management of endometrial precancers |journal=Obstet Gynecol |volume=120 |issue=5 |pages=1160–75 |date=November 2012 |pmid=23090535 |pmc=3800154 |doi=http://10.1097/AOG.0b013e31826bb121 |url=}}</ref> | *Hysterectomy is the mainstay of treatment for [endometrial intraepithelial neoplasia to prevent endometrial carcinoma.<ref name="pmid23090535">{{cite journal |vauthors=Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL |title=Management of endometrial precancers |journal=Obstet Gynecol |volume=120 |issue=5 |pages=1160–75 |date=November 2012 |pmid=23090535 |pmc=3800154 |doi=http://10.1097/AOG.0b013e31826bb121 |url=}}</ref> | ||
Revision as of 12:01, 8 April 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Synonyms and keywords: Atypical endometrial hyperplasia; Minimal uterine serous cancer (MUSC); Serous endometrial intraepithelial carcinoma (EIC); MUSC; Minimal uterine serous cancer
Overview
Endometrial intraepithelial neoplasia lesions have been discovered beginning in the 1990s which provide a multifaceted characterization of this disease. The endometrial intraepithelial neoplasia diagnostic schema is intended to replace the previous "endometrial hyperplasia" classification as defined by the World Health Organization in 1994, which have been separated into benign (benign endometrial hyperplasia) and premalignant (EIN) classes in accordance with their behavior and clinical management.Endometrial intraepithelial neoplasia may be classified according to WHO94 schema classifies histology based on glandular complexity and nuclear atypia into 4 groups: simple hyperplasia, complex hyperplasia, simple hyperplasia with atypia, and complex hyperplasia with atypia. On microscopic histopathological analysis, indiidual glands lined by an pseudostratified epithelium one cell layer thick is a characteristic finding of endometrial intraepithelial neoplasia. Hysterectomy is recommended following the diagnvosis of endometrial intraepithelial neoplasia to prevent endometrial carcinoma.
Historaical Perspective
- Endometrial intraepithelial neoplasia was first discovered by a combination of molecular, histologic, and clinical outcome studies beginning in the 1990s which provide a multifaceted characterization of this disease.
- They are a subset of a larger mixed group of lesions previously called "endometrial hyperplasia" The Endometrial intraepithelial neoplasia diagnostic schema is intended to replace the previous "endometrial hyperplasia" classification as defined by the World Health Organization in 1994, which have been separated into benign (benign endometrial hyperplasia) and premalignant (EIN) classes in accordance with their behavior and clinical management.[1][2]
Classification
- Endometrial hyperplasia may be classified according to new World Health Organization (WHO2014) into two groups:[3]
- Hyperplasia without atypia (non-neoplastic)
- Atypical hyperplasia (endometrial intraepithelial neoplasm)
- Endometrial hyperplasia may be classified according to new World Health Organization (WHO1994) into 4 groups:[4]
- Simple hyperplasia without atypia
- Complex hyperplasia without atypia
- Simple atypical hyperplasia
- Complex atypical hyperplasia
Pathophysiology
- Endometrial intraepithelial neoplasia arises from premalignant glands , which risk of transmutatain to endometrial endometrioid carcinoma.[5]
- Genes involved in the pathogenesis of Endometrial intraepithelial neoplasia (EIN) includ:[6][7][8][9][10]
- Inactivation (mutation or deletion) of the PTEN tumor suppressor gene
- Inactivation of PAX2 gene
- KRAS mutations
- Microsatellite instability
- Mutation in p53 gene
- On microscopic histopathological analysis, individual glands lined by an pseudostratified epithelium one cell layer thick are characteristic finding of endometrial intraepithelial neoplasia.[11][12]
Causes
- Endometrial intraepithelial neoplasia may be caused by either estrogenic stimulation of the endometrium, unopposed by progestins.[13]
Differentiating Endometrial intraepithelial neoplasia from other Diseases
- Endometrial intraepithelial neoplasia must be differentiated from other diseases that cause endometrial disorders such as:[11][14]
- Benign (non atypical hyperplasia)
- Benign endometrial metaplasia (tubal, secretory, mucinous)
- Endometrial glandular dysplasia
- Hyperplastic polyp
- Metastatic carcinoma
- Serous clear cell carcinoma
Epidemiology and Demographics
Prevalence and Incidence
- In 2002, the incidence of endometrial intraepithelial neoplasia (EIN) was estimated to be 144 cases per 100,000 individuals worldwide.[15]
Age
- The incidence of endometrial intraepithelial neoplasia (EIN) increases with age; the median age at diagnosis is 52 years.[16]
Race
- Endometrial intraepithelial neoplasia (EIN) iusually affects individuals of the African American race.Asian individuals are less likely to developendometrial intraepithelial neoplasia.[17]
Risk Factors
- The most potent risk factor in the development of endometrial intraepithelial neoplasia (EIN) is exposure to endogenous (exogenous estrogen without opposing by a progestin).[18]
- Other risk factors include:[19][20][21][22][23][24]
- Aging
- Early menarche
- Late menopause (after age 55)
- Obesity
- Diabetes
- Tamoxifen therapy
- Polycystic ovary syndrome (chronic anovulation)
- Nulliparity
- Infertile women
- Hypertension
- Cowden syndrome
- Lynch syndrome (hereditary conditions such as hereditary nonpolyposis colorectal cancer)
- Family history (endometrial, ovarian, breast, colon cancer)
- White race
- Smoking (Cigarette)
Natural History, Complications and Prognosis
- If left untreated, according to a study, 38% of patients with endometrial intraepithelial neoplasia may progress to develop endometrial cancer.[25]
- Common complications of endometrial intraepithelial neoplasia include:[26]
- Endometrial
- Carcinoma
- Metastases
- Death
- Prognosis of ndometrial intraepithelial neoplasia is generally good with treatment.
Diagnosis
Diagnostic Criteria
- Area of glands is larger than stroma area
- Cytology differs between architecturally crowded focus and background
- size ≥ 1mm
- Forbiddance of adenocarcinoma
- Forbiddance of mimics
| EIN Criterion | Comments | |
|---|---|---|
| 1 | Architecture | Gland area exceeds that of stroma, usually in a localized region. |
| 2 | Cytological Alterations |
Cytology differs between architecturally crowded focus and background. |
| 3 | Size greater than 1mm | Maximum linear dimension should exceed 1mm. Smaller lesions have unknown natural history. |
| 4 | Exclude mimics | Basalis, normal secretory, polyps, repair, lower uterine segment, cystic atrophy, tangential sections, menstrual collapse, disruption artifact, etc. |
| 5 | Exclude Cancer | Carcinoma should be diagnosed if: glands are mazelike and rambling, there are solid areas of epithelial growth, or there are significant bridges or cribriform areas. |
Symptoms
- The hallmark of endometrial intraepithelial neoplasia is postmenopausal bleeding.[28]
- Postmenopausal bleeding
Physical Examination
- Physical examination may be remarkable for:Palpable pelvic masses
Laboratory Findings
- There are no specific laboratory findings associated with endometrial intraepithelial neoplasia.
Imaging Findings
- Transvaginal ultrasonography is indicated for postmenopausal patient who has bleeding to detect malignancy.
- If transvaginal ultrasonography demonstrate an endometrial thickness greater than 4 mm or an inability to adequately visualize endometrial thickness should warrant further evaluation using sonohysterography, office hysteroscopy, or endometrial biopsy.
Other Diagnostic Studies
- Endometrial intraepithelial neoplasia is mainly diagnosed using endometrial suction curette and hematoxylin and eosin staining.
Treatment
Medical Therapy
- Progestin therapy is recommended among patients with endometrial intraepithelial neoplasia and follow-up biopsy every 6 months until 3 negative biopsies .[29][30]
Surgery
- Hysterectomy is the mainstay of treatment for [endometrial intraepithelial neoplasia to prevent endometrial carcinoma.[12]
Prevention
- Hysterectomy is recommended following the diagnosis of endometrial intraepithelial neoplasia to prevent endometrial carcinoma.[31]
References
- ↑ Mutter GL, Duska L, Crum CP (2005). "Endometrial Intraepithelial Neoplasia". In Crum CP, Lee K. Diagnostic Gynecologic and Obstetric Pathology. Philadelphia PA: Saunders. pp. 493–518.
- ↑ Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA (2003). "Tumors of the uterine corpus: epithelial tumors and related lesions". In Tavassoli FA, Stratton MR. WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press. pp. 221–232.
- ↑ Emons G, Beckmann MW, Schmidt D, Mallmann P (February 2015). "New WHO Classification of Endometrial Hyperplasias". Geburtshilfe Frauenheilkd. 75 (2): 135–136. doi:10.1055/s-0034-1396256. PMC 4361167. PMID 25797956.
- ↑ Wang, Steven; Wang, Zhenglong; Mittal, Khushbakhat (2015). "Concurrent endometrial intraepithelial carcinoma (EIC) and endometrial hyperplasia". Human Pathology: Case Reports. 2 (1): 1–4. doi:10.1016/j.ehpc.2014.07.003. ISSN 2214-3300.
- ↑ Jarboe EA, Mutter GL (November 2010). "Endometrial intraepithelial neoplasia". Semin Diagn Pathol. 27 (4): 215–25. PMID 21309257.
- ↑ Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C (June 2001). "Molecular identification of latent precancers in histologically normal endometrium". Cancer Res. 61 (11): 4311–4. PMID 11389050.
- ↑ Faquin WC, Fitzgerald JT, Lin MC, Boynton KA, Muto MG, Mutter GL (April 2000). "Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues". Am. J. Clin. Pathol. 113 (4): 576–82. doi:10.1309/F4TU-6AFE-R7NU-39Y3. PMID 10787358.
- ↑ Monte NM, Webster KA, Neuberg D, Dressler GR, Mutter GL (August 2010). "Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer". Cancer Res. 70 (15): 6225–32. doi:10.1158/0008-5472.CAN-10-0149. PMC 2912978. PMID 20631067.
- ↑ Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C (June 2001). "Molecular identification of latent precancers in histologically normal endometrium". Cancer Res. 61 (11): 4311–4. PMID 11389050.
- ↑ O'Hara AJ, Bell DW (March 2012). "The genomics and genetics of endometrial cancer". Adv Genomics Genet. 2012 (2): 33–47. doi:10.2147/AGG.S28953. PMC 3415201. PMID 22888282.
- ↑ 11.0 11.1 McCluggage WG (August 2006). "My approach to the interpretation of endometrial biopsies and curettings". J. Clin. Pathol. 59 (8): 801–12. doi:10.1136/jcp.2005.029702. PMC 1860448. PMID 16873562.
- ↑ 12.0 12.1 Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL (November 2012). "Management of endometrial precancers". Obstet Gynecol. 120 (5): 1160–75. doi:http://10.1097/AOG.0b013e31826bb121 Check
|doi=value (help). PMC 3800154. PMID 23090535. - ↑ Owings, Richard A.; Quick, Charles M. (2014). "Endometrial Intraepithelial Neoplasia". Archives of Pathology & Laboratory Medicine. 138 (4): 484–491. doi:10.5858/arpa.2012-0709-RA. ISSN 0003-9985.
- ↑ McCluggage, W. Glenn (2011). "Benign Diseases of the Endometrium": 305–358. doi:10.1007/978-1-4419-0489-8_7.
- ↑ Lacey JV, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG (October 2012). "Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan". Int. J. Cancer. 131 (8): 1921–9. doi:10.1002/ijc.27457. PMID 22290745.
- ↑ Carlson JW, Mutter GL (September 2008). "Endometrial intraepithelial neoplasia is associated with polyps and frequently has metaplastic change". Histopathology. 53 (3): 325–32. doi:10.1111/j.1365-2559.2008.03104.x. PMC 2574678. PMID 18637968.
- ↑ Hou, June Y.; McAndrew, Thomas C.; Goldberg, Gary L.; Whitney, Kathleen; Shahabi, Shohreh (2013). "A Clinical and Pathologic Comparison Between Stage-Matched Endometrial Intraepithelial Carcinoma and Uterine Serous Carcinoma". Reproductive Sciences. 21 (4): 532–537. doi:10.1177/1933719113503414. ISSN 1933-7191.
- ↑ Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R (January 2016). "Therapeutic options for management of endometrial hyperplasia". J Gynecol Oncol. 27 (1): e8. doi:10.3802/jgo.2016.27.e8. PMC 4695458. PMID 26463434.
- ↑ Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL (July 2013). "Type I and II endometrial cancers: have they different risk factors?". J. Clin. Oncol. 31 (20): 2607–18. doi:10.1200/JCO.2012.48.2596. PMC 3699726. PMID 23733771.
- ↑ Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H (2001). "American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection". CA Cancer J Clin. 51 (1): 38–75, quiz 77–80. PMID 11577479.
- ↑ Elwood, J. Mark; Cole, Philip; Rothman, Kenneth J.; Kaplan, Samuel D. (1977). "Epidemiology of Endometrial Cancer
2". JNCI: Journal of the National Cancer Institute. 59 (4): 1055–1060. doi:10.1093/jnci/59.4.1055. ISSN 1460-2105. line feed character in
|title=at position 35 (help) - ↑ La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G (September 1984). "Risk factors for endometrial cancer at different ages". J. Natl. Cancer Inst. 73 (3): 667–71. PMID 6590913.
- ↑ Kalin A, Merideth MA, Regier DS, Blumenthal GM, Dennis PA, Stratton P (February 2013). "Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer". Obstet Gynecol. 121 (2 Pt 2 Suppl 1): 461–4. doi:http://10 1097/AOG.0b013e318270444f Check
|doi=value (help). PMC 3799979. PMID 23344409. - ↑ Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R (January 2016). "Therapeutic options for management of endometrial hyperplasia". J Gynecol Oncol. 27 (1): e8. doi:10.3802/jgo.2016.27.e8. PMC 4695458. PMID 26463434.
- ↑ Kalin A, Merideth MA, Regier DS, Blumenthal GM, Dennis PA, Stratton P (February 2013). "Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer". Obstet Gynecol. 121 (2 Pt 2 Suppl 1): 461–4. doi:http://10 1097/AOG.0b013e318270444f Check
|doi=value (help). PMC 3799979. PMID 23344409. - ↑ Soslow RA (January 2016). "Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome". Mod. Pathol. 29 Suppl 1: S59–77. doi:10.1038/modpathol.2015.127. PMC 4821462. PMID 26715174.
- ↑ Owings, Richard A.; Quick, Charles M. (2014). "Endometrial Intraepithelial Neoplasia". Archives of Pathology & Laboratory Medicine. 138 (4): 484–491. doi:10.5858/arpa.2012-0709-RA. ISSN 0003-9985.
- ↑ Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ (April 2007). "Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia". Int. J. Gynecol. Pathol. 26 (2): 103–14. doi:10.1097/PGP.0b013e31802e4696. PMID 17413975.
- ↑ Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL (November 2012). "Management of endometrial precancers". Obstet Gynecol. 120 (5): 1160–75. doi:http://10.1097/AOG.0b013e31826bb121 Check
|doi=value (help). PMC 3800154. PMID 23090535. - ↑ Owings, Richard A.; Quick, Charles M. (2014). "Endometrial Intraepithelial Neoplasia". Archives of Pathology & Laboratory Medicine. 138 (4): 484–491. doi:10.5858/arpa.2012-0709-RA. ISSN 0003-9985.
- ↑ Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL (November 2012). "Management of endometrial precancers". Obstet Gynecol. 120 (5): 1160–75. doi:http://10.1097/AOG.0b013e31826bb121 Check
|doi=value (help). PMC 3800154. PMID 23090535.